Yanghe Huayan decoction inhibits the capability of trans-endothelium and angiogenesis of HER2+ breast cancer via pAkt signaling

Biosci Rep. 2019 Feb 15;39(2):BSR20181260. doi: 10.1042/BSR20181260. Print 2019 Feb 28.

Abstract

Background: Yanghe Huayan Decoction (YHD), a traditional Chinese medicine, is one of the most common complementary medicine currently used in the treatment of breast cancer (BC). It has been recently linked to suppress precancerous lesion and tumor development. The current study sought to explore the role of YHD on trans-endothelium and angiogenesis of BC. Methods: HER2+ BC cells were treated with YHD, Trastuzumab, or the combination in vitro and in vivo to compare the effects of them on trans-endothelium and angiogenesis features. The present study also investigated the potential molecular mechanism of YHD in inhibiting angiogenesis of BC. Results: YHD significantly suppressed the invasion and angiogenesis of BC cells via elevated pAkt signaling. Administration of YHD in vivo also strikingly repressed angiogenesis in tumor grafts. Conclusion: YHD could partially inhibit and reverse tumorigenesis of BC. It also could inhibit Akt activation and angiogenesis in vitro and in vivo Its effect was superior to trastuzumab. Thus it was suitable for prevention and treatment of BC.

Keywords: Yanghe Huayan Decoction; angiogenesis; breast cancer; pAkt signaling; trans-endothelium.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Angiogenesis Inhibitors / pharmacology*
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Breast Neoplasms / blood supply
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Cell Line, Tumor
  • Drugs, Chinese Herbal / administration & dosage
  • Drugs, Chinese Herbal / pharmacology*
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / pathology
  • Female
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Mice, Nude
  • Neovascularization, Pathologic / drug therapy*
  • Proto-Oncogene Proteins c-akt / metabolism*
  • Receptor, ErbB-2 / metabolism
  • Trastuzumab / administration & dosage
  • Xenograft Model Antitumor Assays

Substances

  • Angiogenesis Inhibitors
  • Drugs, Chinese Herbal
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Proto-Oncogene Proteins c-akt
  • Trastuzumab